AU1756299A - Use of putamen ovi - Google Patents

Use of putamen ovi

Info

Publication number
AU1756299A
AU1756299A AU17562/99A AU1756299A AU1756299A AU 1756299 A AU1756299 A AU 1756299A AU 17562/99 A AU17562/99 A AU 17562/99A AU 1756299 A AU1756299 A AU 1756299A AU 1756299 A AU1756299 A AU 1756299A
Authority
AU
Australia
Prior art keywords
putamen ovi
ovi
putamen
medicaments
locally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17562/99A
Inventor
Michel O. Ruepp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MICHEL O RUEPP
Original Assignee
MICHEL O RUEPP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MICHEL O RUEPP filed Critical MICHEL O RUEPP
Publication of AU1756299A publication Critical patent/AU1756299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Paper (AREA)

Abstract

The invention relates to the use of treated putamen ovi in the production of medicaments which can be administered orally or locally for treatment and prevention.
AU17562/99A 1997-11-21 1998-11-20 Use of putamen ovi Abandoned AU1756299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19751681 1997-11-21
DE19751681A DE19751681A1 (en) 1997-11-21 1997-11-21 Use of Putamen ovi
PCT/EP1998/007477 WO1999026641A1 (en) 1997-11-21 1998-11-20 Use of putamen ovi

Publications (1)

Publication Number Publication Date
AU1756299A true AU1756299A (en) 1999-06-15

Family

ID=7849459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17562/99A Abandoned AU1756299A (en) 1997-11-21 1998-11-20 Use of putamen ovi

Country Status (9)

Country Link
EP (1) EP1032407B1 (en)
AT (1) ATE249229T1 (en)
AU (1) AU1756299A (en)
CA (1) CA2311546A1 (en)
DE (2) DE19751681A1 (en)
DK (1) DK1032407T3 (en)
ES (1) ES2207020T3 (en)
WO (1) WO1999026641A1 (en)
ZA (1) ZA9810603B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558771A (en) * 1968-02-12 1971-01-26 Leslie L Balassa Process for using eggshell compositions for promoting wound healing
GB2218906A (en) * 1988-05-27 1989-11-29 Anne Mcmanus Medicament for treatment of skin disorders
CS445488A1 (en) * 1988-06-24 1991-01-15 Karol Mvdr Michalek Biological preparation for osteo- and chondropathies,physiopathological disorders and diseases arisen on base of mineral deficiency in human organism treatment
CN1079149A (en) * 1993-04-09 1993-12-08 李洪洋 A kind of biological calcium element and preparation method thereof
DE4422613A1 (en) * 1994-06-28 1996-01-04 Aar Pharma Adler Apotheke Putamen ovi
NL1002400C2 (en) * 1996-02-20 1997-08-21 Friesland Brands Bv Oral calcitonin preparation and method of recovering calcitonin.
DE19627376A1 (en) * 1996-07-06 1998-01-08 Aar Pharma Adler Apotheke Use of Artichoke (Cynara) extracts
DE19639375A1 (en) * 1996-09-25 1998-04-02 Aar Pharma Mistletoe dry extracts
DE19700788A1 (en) * 1997-01-11 1998-07-16 Michael O Ruepp Use of a dry extract of St. John's wort

Also Published As

Publication number Publication date
EP1032407B1 (en) 2003-09-10
ES2207020T3 (en) 2004-05-16
EP1032407A1 (en) 2000-09-06
ZA9810603B (en) 1999-08-02
DE59809592D1 (en) 2003-10-16
DK1032407T3 (en) 2004-01-12
ATE249229T1 (en) 2003-09-15
DE19751681A1 (en) 1999-07-29
CA2311546A1 (en) 1999-06-03
WO1999026641A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
NO954996D0 (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO1995031991A3 (en) Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
GB0020504D0 (en) Therapeutic method
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
NZ326345A (en) Composition containing diosgenin
NZ533309A (en) Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
NO990450L (en) Treatment of mental disorders
AU1756299A (en) Use of putamen ovi
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
AU2811400A (en) Stable formulation containing fumagillin
AU6004300A (en) Treatment of angiogenesis dependent conditions with dextrin sulphate
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
UA32580C2 (en) Drug for treatment of paralytic intestinal obstructioni
WO2000067733A3 (en) Medicament for treating human infertility
MX9605327A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration.
UA27148C2 (en) Method for treating acute pyelonephritis
MD1664G2 (en) Method of ulcer recidivation prophylaxis
MD950122A (en) Method of treatment of depressive state for oncological postinsult ill people

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase